MediZen Ltd has been involved in conducting clinical trials since 2004, across a range of procedures and product types including toxins, dermal fillers, injectable submental fat reduction, fibroblast implantation and LED Phototherapy Treatments.

MediZen has been registered with the Care Quality Commission (CQC) since 2005 and have been independently audited and have met all standards required when we have been inspected through unannounced visits from the CQC In 2012 we were audited by the Medicines and Healthcare Products Regulatory Agency (MHRA) as we were the largest single investigative site in the UK for a phase III registration study on a novel lipolytic drug.

Over the last few years MediZen has continued to develop its involvement in this area and as a consequence, now has a dedicated unit and resource for the administration, subject recruitment and implementation of clinical trial activity. As a result, the number and scope of trials we are involved with at any one time have increased, as has our reputation amongst some of the worlds largest Pharmaceutical companies, for being able to ensure that trial activity is conducted to the highest levels of compliance and accuracy. In addition, we have a proven history of submitting and getting trial protocols approved by local ethics committees.

Handling the planning, scheduling, recruitment and administration of the Clinical Trials conducted at MediZen are Ruth and Ian. Their work is essential in ensuring trials run smoothly and follow the strict protocols.

On the clinical side sits MediZen's Clinical Director, Dr David Eccleston, who has 20 years experience in Medical Aesthetics.

He is also a Private GP in Sutton Coldfield, having also spent over 22 years as an NHS GP, and is in regular demand as a teacher and trainer in Medical Aesthetics. David has trained and been involved in advisory panels with worldwide opinion leaders including Jean and Alastair Carruthers, Koenraad de Boulle, Zein Obagi and Mauricio De Maoi. Since 2006 he has been acknowledged as a Key Opinion Leader and Advisory Board Member for Allergan Inc and has presented and trained all over Europe and further afield, including Turkey, South Africa, Saudi Arabia, Jordan and the USA in various cosmetic techniques. David has also appeared in and authored many magazine articles and taken part in television and radio interviews on the subject of non-surgical medical aesthetics.

Since 1992 Dr Eccleston has participated as a lead investigator in numerous clinical trials, at both pre-and post-marketing stages, covering many therapeutic areas. Most recently these include:

 1) A comparative study in the treatment of glabellar frown lines – 2004

 2) A study to assess the effectiveness of a hand-held blue LED light device in the treatment of facial acne vulgaris – 2006

 3) A double-blind placebo-controlled study in the treatment of crows feet – 2007

 4) A study using human allogeneic fibroblast transplantation in the treatment of facial scars – 2008

 5) Comparative study in the treatment of glabellar folds – 2009

 6) Assessment of a novel hyaluronic acid lip filler - 2010

 7) Crow’s feet study - 2011

 8) Comparative study of an injectable submental fat reduction substance - 2011

 9) A blinded comparative study of Restylane vs Juvederm Volbella in lip enhancement – 2012

10) The use of Juvederm Voluma in facial recontouring – 2012

11) Eyelash thickening and lengthening - 2013

12) Evaluation of efficacy and compliance of a novel at-home blue light device for acne - 2013

13) Evaluation of the safety and efficacy of treatment for subjects with facial forehead, glabella and lateral canthal lines for Allergan - 2014 - 2016

14) Randomised blind and then open-label study to investigate the efficacy and safety of BTX-A-HAC NC in the treatment of moderate to severe glabellar line and assess the long-term efficacy and safety of the product following repeated treatments in this indication - 2015 - 2016 

15) Study regarding a temperature controlled methodology for the Indiba radio frequency device for skin tightening - 2016 - 2017

16) Allergan study on reduction of crows feet - 2018

17) Topical anticholinergic study for the treatment of axillary hyperhidrosis - 2018

18) Allergan study on a new type of lip filler for reshaping and augmenting lips - 2018